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Background: NLRP3 inflammasome is proposed to regulate inflammation in several neurological diseases, but its
role in epilepsy remains largely unknown. This study aimed to investigate the role of the NLRP3 inflammasome in
neuroinflammation, spontaneous recurrent seizures (SRS) and hippocampal neuronal loss in rat brain following
amygdala kindling-induced status epilepticus (SE).
Methods: We detected the protein levels of IL-1β and NLRP3 inflammasome components by Western blot in the
hippocampus of shams and SE rats at different time points following SE. To further examine whether the activation
of the NLRP3 inflammasome contributes to SE-associated neuronal damage, we employed a nonviral strategy to
knock down NLRP3 and caspase-1 expression in brain before undergoing SE. Proinflammatory cytokine levels and
hippocampal neuronal loss were evaluated at 12 hours and at 6 weeks following SE respectively in these NLRP3
and caspase-1 deficient rats. Meanwhile, SRS occurrence was evaluated through a 4-week video recording started
2 weeks after SE in these NLRP3 and caspase-1 deficient rats.
Results: IL-1β levels and NLRP3 inflammasome components levels dramatically increased at 3 hours after SE, and
reached a maximum at 12 hours after SE compared with the control group. Knock down of NLRP3 or caspase-1
decreased the levels of IL-1β and IL-18 at 12 hours after SE, which was accompanied by a significant suppression
in the development and severity of SRS during the chronic epileptic phase. Meanwhile, knock down of NLRP3
or caspase-1 led to a remarkable reduction of hippocampal neuronal loss in the CA1 and CA3 area of the
hippocampus at 6 weeks after SE.
Conclusions: Our study provides the first evidence that the NLRP3 inflammasome was significantly up-regulated
following SE. More importantly, we show that inhibition of the NLRP3 inflammasome provides neuroprotection
in rats following SE. These findings suggest that NLRP3 may represent a potential target for the treatment of
epileptogenesis
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Status epilepticus (SE), which is one of the most ser-
ious manifestations of epilepsy, can be defined as 'a
condition characterized by an epileptic seizure that is
so frequent or so prolonged as to create a fixed and
lasting condition' [1]. Brain inflammation promotes in-
creased neuronal excitability, decreases seizure thresh-
old and is likely to be involved in the molecular,
structural and synaptic changes characterizing epilepto-
genesis [2]. Among all the enhanced proinflammatory
cytokines following SE, IL-1β is regarded as a pivotal
therapeutic target in SE, as observations have demon-
strated IL-1β as being an important inflammation-
related epileptogenic factor [3 ? 5]. Many anti-seizure
drugs are known to decrease IL-1β levels [6,7]. More-
over, the inhibition or deletion of caspase-1, the en-
zyme which cleaves pro-IL-1β producing the mature
and biologically active form of IL-1β, attained signifi-
cant seizure reduction [8,9]. However, the mechanisms
by which the production of IL-1β is regulated have not
been established.
The nucleotide binding and oligomerization domain-
like receptor family pyrin domain-containing 3 (NLRP3)
inflammasome is a multiprotein complex that mediates
the activation of caspase-1, which in turn cleaves
pro-IL-1β to form the mature IL-1β and is found to be a
pivotal mediator of IL-1β function [10]. The NLRP3
inflammasome [11], composed of NLR family, pyrin do-
main containing 3 (NLRP3), apoptosis-associated speck-
like protein containing a caspase recruitment domain
(ASC) and caspase-1, mediates IL-1β transcription and
functions via coupling with the NF-κB inflammatory
pathway [12]. The NLRP3 inflammasome has been dem-
onstrated as being associated with the innate immunity
and inflammatory regulation of the central nervous sys-
tem (CNS) [13 ? 15]. It should be noted that the high
concentrations of extracellular ATP and K+ ions, the
generation of reactive oxygen species (ROS), the increased
intracellular Ca2+ concentration, acidosis, hypoxia and cell
swelling can activate NLRP3 [16? 18]. Actually, all of the
above factors underlie the generation of SE [19? 22]. We
hypothesized that this inflammasome may have potential
to induce IL-1β-related neuroinflammation in SE. There-
fore, it is intriguing to investigate the role of the NLRP3
inflammasome in SE-associated pathology and func-
tional outcomes.
To test this hypothesis, we first investigated the ex-
pression profiles of IL-1β and NLRP3 inflammasome
components, including NLRP3 and caspase-1 after SE.
Next, we applied small interfering RNAs (siRNAs) to
knock down NLRP3 and caspase-1 in vivo, and mea-
sured the alteration in proinflammatory cytokine and
NLRP3 inflammasome components as well as the effects
on functional outcomes.Methods
Animals and experiments groups
To avoid the interference of estrogen on microglial activa-
tion, neuroinflammation and cognitive function [23], only
male rats were used in this study. Adult male Sprague-
Dawley (SD) rats weighing 260 to 300 g were obtained from
the Experimental Animal Center of Qingdao University.
The rats were specific-pathogen free rats, regularly checked
to ensure the status, and housed in a pathogen-free room
with a 12-hour light/dark cycle and given free access to
food and water. All experiments were performed in strict
accordance with the National Institute of Health Guide for
the Care and Use of Laboratory Animals. Animal care and
sacrifice were conducted according to methods approved
by the Qingdao University Animal Experimentation
Committee, and all efforts were made to minimize the
number of animals used and their suffering. Experimental
group allocation and experimental design are shown in
Additional file 1: Figure S1.
siRNA administration in rat brain
The NLRP3 siRNA was designed and synthesized by
Invitrogen (Carlsbad, CA, USA). Caspase-1 siRNA and
control siRNA were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Entranster ? -
in vivo transfection reagent was purchased from Engreen
Biosystem Co, Ltd (Beijing, China). We prepared the
Entranster ? -in vivo-siRNA mixture according to the
manufacturer ? s instructions. Briefly, 50 μg siRNA were
resuspended in 50 μL RNase-free water to make a siRNA
solution. Then, 50 μL of siRNA solution were mixed with
50 μL of Entranster? -in vivo transfection reagent and
100 μL artificial cerebrospinal fluid (aCSF, composition in
mmol/L: NaCl 130, KCl 2.99, CaCl2 0.98, MgCl2? 6H2O
0.80, NaHCO3 25, Na2HPO4 ? 12H2O 0.039, NaH2-
PO4? 2H2O 0.46) to obtain a 200 μL Entranster? -in vivo
transfection mixture. Then, the 200 μL Entranster? -in vivo
transfection mixture (containing NLRP3 or caspase-1
siRNA, control siRNA, no siRNA (aCSF only)) was filled
into an osmotic pump (Model 2006; ALZET, Cupertino,
CA, USA). Meanwhile, rats were anesthetized with 10%
chloral hydrate (0.3 mL/100 g, intraperitoneal) and were
placed in a stereotaxic apparatus (Stoelting, Wood Dale,
IL, USA). A brain-infusion cannula (Brain Infusion Kit 2;
ALZET, Cupertino, CA, USA) coupled via vinyl tubing to
the osmotic pump was implanted into the dorsal third ven-
tricle (AP: −1.8 mm; L: −0 mm; V: −5 mm). The osmotic
pump was placed subcutaneously between the rat scapulae,
and the siRNAs were continuously infused into the brain
over a 6-week duration at a flow rate of 0.15 μL/hour. This
dose of NLRP3 siRNA or caspase-1 siRNA infusion was
well tolerated, and no signs of neurotoxicity including
hind-limb paralysis, vocalization, food intake, or neuro-
anatomical damage were observed in preliminary study.
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tween control siRNA-treated and non-siRNA-treated
rats do not differ. All of the operations were carried out
with aseptic techniques.
Electrode implantation and SE induction
SE was triggered following the methods of our previous
work [24]. Briefly, rats were fixed in a stereotactic apparatus
(Stoelting, Wood Dale, IL, USA) under deep anesthesia
(10% chloral hydrate, 0.3 mL/100 g, intraperitoneal). The
electrodes were permanently implanted into the right baso-
lateral amygdala (AP: −3.0 mm; L: −4.8 mm; V: −8.8 mm)
and were connected to a miniature receptacle, embedding
in the skull with screws and dental acrylic cement. After
electrode implantation, the animals were allowed to recover
from surgery for 2 weeks. SE was induced by continuous
delivery of 100-ms trains, consisting of 60 Hz 400 μA
(peak-to-peak) bipolar 1-ms square-wave pulses, delivered
at 60 Hz every 0.5 seconds using a ML1101 electronic
stimulator (Nihon Kohden) via the implanted electrode
for up to 20 minutes. Electroencephalograms (EEGs) of
the right amygdala were recorded with a digital amplifier
(AD Instrument, Bio Amp (Shanghai, China), USA). After
20 minutes of continuous stimulation the stimulation was
interrupted and the behavioral and electrographic activity
of the animals was observed for 60 seconds. If the behav-
ior of the animals indicated the presence of epileptic
activity (head nodding or limb clonus), observation was
continued for another 5 minutes. If an animal did not
meet the criteria of clonic SE (continuous EEG epilepti-
form spiking and recurrent clonic seizures), stimulation
was resumed and the behavior of the animal was checked
again after 5 minutes. Once the criteria of SE were
achieved, no further stimulation was given. Stimulation
period never exceeded 40 minutes. All of the operations
were carried out with aseptic techniques. Sham rats
were handled in the same manner but without receiving
any electrical stimulation. Moreover, our preliminary
experiments also show that this amygdala stimulation
model is effective.
Monitoring of SRS
SRS occurrence was evaluated through a 4-week video
monitoring started 2 weeks after SE. All recordings for
SRS were done during the light period. Epileptic rats
were video-recorded for at least 12 hours daily. The fre-
quency and duration of stage 4/5 seizures were recorded,
and the severity of SRS was scored according to Racine ? s
scale [25]. The recordings were analyzed by observers
who were blind to the results of group allocation.
Brain tissue preparation
Rats were sacrificed under deep anesthesia and were han-
dled as follows: For Western blot analysis, quantitativereal-time PCR, and ELISA, rats were perfused transcar-
dially with 0.9% saline (pH 7.4) only. The brains were
removed rapidly and stored in liquid nitrogen until use.
For cresyl violet staining and terminal deoxynucleotidyl
transferase-mediated dUTP end-labeling assay (TUNEL)
analysis, rats were perfused transcardially with 0.9% saline
(pH 7.4), followed by a fixative solution containing 4%
paraformaldehyde in 0.9% saline (pH 7.4). The brains were
removed and fixed in the same fixative at 4?C until use.
For double immunofluorescence staining, rat brain was
removed without perfusion, embedded in tissue freezing
medium, and immediately frozen at −4?C. Frozen tissue
was stored at −80?C until sectioning.
Western blotting
Tissues samples were digested with radio immunopre-
cipitation assay (RIPA) lysis buffer (50 mmol/L Tris-HCl,
150 mmol/L NaCl, 1% Nonidet-40, 0.5% sodium deoxy-
cholate, 1 mmol/L EDTA, 1 mmol/L PMSF) with protease
inhibitors (pepstatin 1 μg/mL, aprotinin 1 μg/mL, leupep-
tin 1 μg/mL) for 30 minutes and centrifuged at 12,000 ? g
for 15 minutes at 4?C. The protein concentration was de-
termined using the Bradford assay kit (Bio-Rad Laborator-
ies, Hercules, CA, USA). The equal amount of protein
from different samples was separated using 8 to12% so-
dium dodecyl sulfate (SDS) polyacrylamide gels and trans-
ferred to polyvinylidene fluoride (PVDF) membranes. The
membranes were blocked with 10% non-fat milk in
Tween-TBS (TBST) and incubated at 4?C overnight,
with the primary antibodies against NLRP3 (1:200; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), cleaved IL-1β
(1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
cleaved caspase-1 (1:200; Biorbyt, San Francisco, CA, USA),
and β-actin (1:1,000; Santa Cruz Biotechnology, Santa Cruz,
CA, USA). After rinsing, the membranes were appropri-
ately incubated with horseradish peroxidase (HRP)-conju-
gated suitable secondary antibodies (1:5,000; Zhongshan
Inc., Beijing, China) for 2 hours at room temperature.
Cross-reactivity was visualized using electrochemilumines-
cence (ECL) Western blotting detection reagents and ana-
lyzed by scanning densitometry using a UVP BioDoc-It
Imaging System (UVP, Upland, CA, USA).
Quantitative Real-Time PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA), using the protocol supplied by
the manufacturer. The cDNA was synthesized using
Reverse Transcription System (Bio-Rad, Hercules, CA,
USA). The reaction was performed at 42 ?C for 50 mi-
nutes, 95?C for 5 minutes, and 5?C for 5 minutes, then
the cDNA was stored at −20?C. Amplification was car-
ried out using the Stratagene Mx3000P real-time PCR
system (Stratagene, La Jolla, CA, USA) and real-time
SYBR Green PCR technology (Takara Bio, Inc., Shiga,
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volume of 20 μL containing 2 μL cDNA, 10 μL SYBR
Green, 0.4 μL ROX Reference Dye, 0.4 μL forward and
reverse primer (1 mol/L), and 6.8 μL nuclease-free water.
The optimal conditions were 40 cycles of 95?C for 30 sec-
onds, 60?C for 32 seconds, and 72?C for 30 seconds. All
reactions were run in duplicates and the mean values are
used. Total RNA concentrations from each sample were
normalized by quantity of β-actin mRNA, and the target
genes? expression was evaluated by ratio of the number of
target mRNA to β-actin mRNA. Relative expression of
genes was obtained by the 2-△△CT method. Primers were
purchased from Invitrogen (Carlsbad, CA, USA) as fol-
lows (name: forward primer, reverse primer): nlrp3: 5? -cc
agggctctgttcattg-3? , 5? -ccttggctttcacttcg-3? ; caspase-1: 5? -ag
gagggaatatgtggg-3? , 5? -aaccttgggcttgtctt-3? ; β-actin: 5? -agg
gaaatcgtgcgtgac3? , 5? -cgctcattgccgatagtg-3? .Cytokine measurement
The cytokine analysis was performed in duplicate using
commercial ELISA assay kits according to the manufac-
turers ? instructions. IL-1β was measured in ELISAs from
R&D Systems (Minneapolis, MN, USA). IL-18 was mea-
sured in ELISAs from Invitrogen (Carlsbad, CA, USA).
The results are expressed in pg/mL.Nissl staining (cresyl violet staining) and TUNEL staining
The brains were embedded in paraffin and cut into
7-μm sections. Nissl staining was employed to detect sur-
viving neurons. Briefly, the paraffin-embedded sections
were dewaxed and rehydrated according to the standard
protocols, and immersed in 1% cresyl violet at 50?C for
5 minutes. After being rinsed with water, the sections were
dehydrated in increasing concentrations of ethanol,
mounted on the slides, and examined with a light micro-
scope. Only the neurons with a violet nucleus and intact
morphology were counted as surviving neurons. The
TUNEL staining, which detects DNA fragmentation
resulting from apoptotic signaling cascades, was per-
formed to label apoptotic neurons. It may also label cells
that have suffered severe DNA damage. Therefore, the
TUNEL assay is helpful in identifying seizure-induced
neuronal loss in our experiment. We employed the
TUNEL assay via a commercial kit according to the man-
ufacturer's instructions (Roche Co., Mannheim, Germany).
TUNEL-positive neurons with condensed nuclei were
identified as dead neurons. Cell counting was performed
on six randomly selected non-overlapping fields in the
CA1 and CA3 regions of the hippocampus per slide. The
densities of surviving neurons or TUNEL-positive neurons
in the hippocampus of the scanned digital images were
calculated using Image-Pro Express software (Media
Cybernetics, Silver Spring, MD, USA). The total cellcounts were averaged from six sections per animal. The
survival index was defined as:
Surviving index %? ?
? 100 ? Number of survivng neurons
=Total numbers of neurons ?
Furthermore, the TUNEL-positive neuron index was
defined as:
TUNEL−positive neurons index %? ?
? 100 ? Count of TUNEL−positive neurons
=Total count of neurons ?
Double immunofluorescence staining
In brief, frozen tissue sections of hippocampus area
(20 μm thick) from epileptic rats at 12 hours following
amygdala stimulation and time-matched shams were used
for double staining of NLRP3/ionized Ca+ binding adaptor
molecule 1 (Iba1). The sections were obtained by cryosec-
tioning at −20?C, mounted on a glass slide, and incubated
at room temperature for 1 hour. Afterward, the sections
were fixed in ice-cold acetone for 10 minutes and then
dried on a heater for 10 minutes at 40?C. The sections
were then blocked with 5% BSA and 0.1% Triton X-100
for 2 hours at room temperature. After a single wash with
PBS, sections were incubated overnight at 4?C with a goat
polyclonal antibody against Iba1 (1:100, Abcam, Cambridge,
UK) as well as a rabbit polyclonal antibody against NLRP3
(1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA)).
Sections were rinsed in PBS and washed 3 times, and then
incubated respectively with tetramethylrhodamine (TRITC)-
conjugated anti-goat IgG (1:200; Zhongshan Inc., Beijing,
China) and fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit IgG (1:200; Santa Cruz Biotechnology) for
2 hours at room temperature in a dark and humidified
container. After that, the sections were washed with PBS
and sealed with a coverslip. The slides were analyzed with a
fluorescence microscopy (Olympus, Tokyo, Japan). For
nuclear staining we used 4',6-diamidino-2-phenylindole
(DAPI). To ensure the specificity of the immunoblotting
procedure, control experiments were performed in which
the corresponding primary antibody was omitted. Under
these conditions, no signal was observed.
Statistical analysis
Statistical analysis was carried out by SPSS software 17.0
(IBM Inc., Chicago, IL, USA). After confirming normal
distribution with skewness and kurtosis statistic test, in-
dependent sample t-test or one-way analysis of variance
(ANOVA) followed by the Bonferroni post hoc test used
to analyze differences among groups. All data were pre-
sented as mean ? standard deviation (SD). P < 0.05 was
considered statistically significant.
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Cleaved IL-1β, NLRP3 and cleaved caspase-1 were
up-regulated in SE rat
We first investigated whether the expression of IL-1β
was altered in rat brain after SE which was induced by
amygdala stimulation. Total proteins were extracted from
the hippocampal regions of SE rats at different time points
(including 3, 6, 12, 24 hours following SE) and of shams,
and subjected to Western blot analysis. Because there was
no significant difference in all detected variables among
different sham groups according to our preliminary ana-
lysis, the samples of sham group were collected at 12 hoursFigure 1 Expression profiles of the nucleotide binding and oligomeri
(NLRP3) inflammasome components following status epilepticus (SE).
(18 kDa) (A), NLRP3 (106 kDa) (B) and cleaved caspase-1 (20 kDa) (C) in the
of amygdala stimulation (without any electrical stimulation) and SE rat at 3
expressed as a fold change relative to sham group. n = 6 rat per group and
*P < 0.05 versus sham control group. NS: not significant versus 12 hours fol
staining for NLRP3 (green) expression in microglia (Iba-1, red) in the hippocafter the sham operation of amygdala stimulation (without
any electrical stimulation). We found that the cleaved
IL-1β levels of SE rats were significantly elevated com-
pared to control samples during all time points studied
(Figure 1A). In the SE group, cleaved IL-1β levels dra-
matically increased at 3 hours and reached a maximum
at 12 hours (about 4 ? those of the sham group ) after
SE (P < 0.05; n = 6). Following this maximum, no statis-
tically significant difference was observed in expression
level of cleaved IL-1β among rat brains at 24 hours
compared with that at 12 hours (P = 1.000; n = 6). Next,
we analyzed the expression of hippocampal NLRP3zation domain-like receptor family pyrin domain-containing 3
(A-C) Western blot assay for the expression profiles of cleaved IL-1β
hippocampus of sham rat at 12 hours following the sham operation
, 6, 12, and 24 hours following amygdala stimulation. Data are
per time point. Error bars represent mean ? standard deviation.
lowing SE. (D) Representative photographs of immunofluorescence
ampal area 12 hours following SE. Scale bars: 100 μm.
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levels of hippocampal NLRP3 protein, and caspase-1
p20, the products of NLRP3 inflammasome activation,
were significantly increased at 3 hours and reached a
maximum at 12 hours after SE (both P < 0.05; n = 6,
Figure 1B, C). Accordingly, no significant differences
were observed in NLRP3 levels (P = 1.000; n = 6), and
cleaved caspase-1 levels (P = 1.000; n = 6) among rat
brains at 24 hours compared with that at 12 hours after
SE. Using double immunofluorescence staining to colocal-
ize NLRP3 with microglia marker Iba1, our result further
demonstrated the increased expression of NLRP3 in the
Iba1-positive microglia of hippocampus at 12 hours fol-
lowing SE (Figure 1D).Figure 2 Downregulation of nucleotide binding and oligomerization
by siRNA led to significant reduction of proinflammatory cytokines an
(18 kDa) was detected by Western blot analysis and ELISA. β-actin was use
detected by ELISA. (C) The protein expression level of active caspase-1 (20
level of caspase-1 was detected by quantitative real-time PCR. Data are exp
All data are shown as mean ? standard deviation (n = 6 per group). * P < 0.0Downregulation of NLRP3 by siRNA led to significant
reduction in proinflammatory cytokines and cleaved
caspase-1 expression levels in SE rat
To directly study the potential impact of increased
NLRP3 expression levels on the maturation and secre-
tion of IL-1β in SE rats, we knocked down brain NLRP3
expression in animals before undergoing SE by using
in-vivo nonviral RNA interference methodology [26]. To
evaluate the silencing efficiency of siRNA infusion, the
gene expression and protein level of NLRP3 protein were
detected by quantitative real-time PCR and Western blot-
ting, respectively. This approach of using NLRP3 siRNA
infusion could produce a significant down-regulation of
NLRP3 mRNA (by 60%) and protein levels (by 51%) in thedomain-like receptor family pyrin domain-containing 3 (NLRP3)
d cleaved caspase-1. (A) The expression level of cleaved IL-1β
d as loading control. (B) The expression level of cleaved IL-18 was
kDa) was analyzed using the Western blot assay. The gene expression
ressed as a fold change relative to SE rat infused with control siRNA.
5 versus control siRNA treatment.
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ditions (all P < 0.05; Additional file 2: Figure S2 A, B). Inci-
dentally, the NLRP3 levels and gene expression between
control-siRNA treated and non-siRNA-treated tissues
under epileptic conditions or under control conditions do
not differ (all P > 0.05; n = 6, Additional file 2: Figure S2 A,
B, and E), excluding potential indirect siRNA-effects on
gene expression or the protein level of NLRP3.
Next, we determined the effects of NLRP3 knock down
on SE-induced neuroinflammation. The proinflammatory
cytokines expression levels were then assessed by Western
blot analysis and ELISA assay. Compared to the control-
siRNA group, the elevated expression level of cleaved
IL-1β in the brain tissues of SE rats could be inhibited
by NLRP3 siRNA treatment (P < 0.05; n = 6; Figure 2A).
In addition, SE rats infused with NLRP3 siRNA showed
a dramatic reduction in brain IL-18 protein levels
(P < 0.05; n = 6; Figure 2B). We further examined the
changes in caspase-1, which has been known to play a
central role in the cleavage of IL-1β and IL-18. The gene
expression and protein level of caspase-1 protein were
detected by quantitative real-time PCR and Western
blotting, respectively. As indicated in Figure 2C, the
NLRP3 siRNA treatment could reduce the active caspase-
1 protein levels and gene expression in SE rats (both
P < 0.05; n = 6).
Downregulation of NLRP3 by siRNA attenuated the
development and severity of spontaneous recurrent
seizures following SE
In above work, we demonstrated that NLRP3 mediated
IL-1β over-expression and inflammatory signal activa-
tion in the SE rat hippocampus. Accumulating data sug-
gest that inflammation may contribute to epileptogenesisTable 1 The development and severity of animals with spont
monitoring in experimental groups
(A) Results from rats after 6 weeks of treatment with NLRP3 siRNA or c
The number of rats
developing SRS
The time to dev
of SRS (days)
Control siRNA + sham 0 (18) 0
NLRP3 siRNA+ sham 0 (18) 0
Control siRNA + SE 18 (18) 14.8 ? 5.5
NLRP3 siRNA+ SE 12 (18)a 27.5 ? 9.3 a
(B) Results from rats after 6 weeks of treatment with caspase-1 siRNA o
The number of rats
developing SRS
The time to dev
of SRS (days)
Control siRNA + sham 0 (18) 0
Caspase-1 siRNA + sham 0 (18) 0
Control siRNA+ SE 17 (18) 16.6 ? 6.1
Caspase-1 siRNA+ SE 11 (18)a 26.8 ? 9.1 a
All data are shown as mean ? standard deviation (n = 18 per group). aP < 0.05 versuin experimental models as well as in humans. However,
whether anti-inflammatory treatments can prevent epi-
leptogenesis remains controversial. Here, we examined
the anti-epileptogenic effect of NLRP3 inhibition.
To determine the effect of NLRP3 siRNA on the de-
velopment and severity of SRS in the chronic phase,
SRS were observed from a 4-week video recording,
which started 2 weeks after SE. The severity of SRS be-
tween siRNA (non or control)-treated SE rats and SE
rats do not differ (all P > 0.05; n = 18, Additional file 3:
Table S1), excluding an effect of siRNA transfection on
status severity.
As revealed by Table 1(A), all rats (18/18) in the control
siRNA-treated SE group had SRS during the monitoring
period, whereas 66% (12/18) of the rats in the NLRP3
siRNA-treated SE group had SRS. The time to develop-
ment of SRS was longer in the NLRP3 siRNA-treated SE
group compared with the control siRNA-treated SE group
(SE + control siRNA group: 14.8 ? 5.5 days; SE +NLRP3
siRNA group: 27.5 ? 9.3 days, Table 1A). The mean num-
ber of seizures (total number of seizures/number of
recording days, calculated separately for each animal) in
the control siRNA-treated SE group and NLRP3 siRNA-
treated SE group was 7.58 ? 1.09 and 1.34 ? 0.44 seizures/
day respectively. NLRP3 siRNA treatment also dramatic-
ally reduced the duration of observed seizures during the
chronic epileptic phase (control siRNA, 26.62 ? 6.94 sec-
onds; NLRP3 siRNA, 10.48 ? 2.76 seconds, Table 1A).
The differences between the two groups were significant
(P < 0.05, Table 1A).
NLRP3, nucleotide binding and oligomerization domain-
like receptor family pyrin domain-containing 3; SE,
status epilepticus; sec, seconds; SRS, spontaneous recur-
rent seizures.aneous recurrent seizures (SRS) during the 4-week video
ontrol siRNA






7.58 ? 1.09 26.62 ? 6.94
1.34 ? 0.44 a 10.48 ? 2.76 a
r control siRNA






9.02 ? 1.56 23.67 ? 5.90
2.40 ? 0.78 a 8.21 ? 2.66 a
s control siRNA treatment.
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hippocampal neuronal loss in SE rat
If left untreated, SE can cause irreversible brain damage.
On this basis, we next investigated the effects of NLRP3
inhibition on neuronal loss in the CA1 and CA3 area of
the hippocampus at 6 weeks after SE. Nissl staining was
firstly used to detect surviving neurons in the hippocam-
pus. As shown by Figure 3A, a significant increase in
neuronal survival rate was noted in CA1 and CA3 regions
in the hippocampus of SE rats treated with NLRP3 siRNA
compared to the control-siRNA group (CA1: 77.34 ? 5.7%
versus 59.57 ? 5.8%, P < 0.05; CA3: 83.43 ? 7.3% versus
62.1 ? 6.5%, P < 0.05). The TUNEL staining assay was then
used. As indicated by Figure 3B, a dramatic reduction of
the TUNEL-positive neurons index was observed in CA1
and CA3 regions of the hippocampus of SE rats treatedFigure 3 Downregulation of nucleotide binding and oligomerization
by siRNA attenuated hippocampal neuronal loss in status epilepticus
CA3 region of the rat hippocampus. Neurons with intact morphology were
survival rate was defined as follows: Neuronal surviving rate (%) = 100 ? (Cou
was detected using the TUNEL staining in the hippocampus of sham rats a
better contrast ratio. Neurons with deep black nuclei were identified as TU
The percentage of TUNEL-positive neurons was defined as follows: 100 ? (Co
represent mean ? standard deviation (n = 6 per group). * P < 0.05 versus con
mediated dUTP end-labeling.with NLRP3 siRNA compared to the control-siRNA
group (CA1: 11.41 ? 2.4% versus 15.95 ? 3.3%, P < 0.05;
CA3: 9.9 ? 1.9% versus 13.29 ? 2.8%, P < 0.05).
Downregulation of caspase-1 by siRNA alleviated
neuroinflammation, spontaneous recurrent seizures and
hippocampal neuronal loss following SE
Considering the central role of caspase-1 in the process of
IL-1β maturation and secretion, we also successfully
knocked down brain caspase-1 in SE rat by in-vivo nonvi-
ral RNA interference methodology for 6 weeks (Additional
file 2: Figure S2 C, D, and F). We found a significant re-
duction of IL-1β levels after infused with caspase-1 siRNA
(P < 0.05; n = 6, Figure 4A). Furthermore, caspase-1 silen-
cing attenuated the development and severity of SRS in
the chronic phase (P < 0.05; n = 18, Table 1B). A markeddomain-like receptor family pyrin domain-containing 3 (NLRP3)
(SE rat). (A) Representative photo of Nissl-staining in CA1 region and
identified as surviving neurons. Scale bars: 50 μm. The neuronal
nt of surviving neurons/Total count of neurons). (B) Neuronal death
nd SE rats. Photos were converted to black and white to obtain a
NEL-positive neurons (indicated by red arrows). Scale bars: 50 μm.
unt of TUNEL-positive neurons/Total count of neurons). Columns
trol siRNA treatment. TUNEL, terminal deoxynucleotidyl transferase-
Figure 4 Caspase-1 inhibition ameliorated neuroinflammation and hippocampal neuronal loss in status epilepticus (SE) rat. (A) The
expression level of cleaved IL-1β (18 kDa) was detected by Western blot. β-actin was used as loading control. Data are expressed as a fold change
relative to SE rat infused with control siRNA. *P < 0.05 versus control siRNA treated group. (B) Neuronal death was detected using the TUNEL
staining in the CA1 and CA3 region of the hippocampus. Photos were converted to black and white to obtain a better contrast ratio. Neurons
with deep black nuclei were identified as TUNEL-positive neurons (indicated by red arrows). Scale bars: 50 μm. The percentage of TUNEL-positive
neurons was defined as follows: 100? (Count of TUNEL-positive neurons/Total count of neurons). All data are shown as mean ? standard deviation
(n = 6 per group). *P < 0.05 versus control siRNA-treated group. TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP end-labeling.
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and CA3 region of the hippocampus in the SE rat treated
with caspase-1 siRNA was also observed (P < 0.05; n = 6,
Figure 4B).
Discussion
Experimental evidence supports a role for inflammatory
processes in the precipitation and recurrence of seizures
and neuronal damage. The involvement of proinflamma-
tory cytokine IL-1β in the development of seizure is
strongly supported by pharmacological and genetic stud-
ies in animal models, showing that interference with
IL-1β reduces the incidence of SE or attenuates recurrent
seizures [8,27,28], whereas its amplification exacerbates
seizures [27,29,30] as well as lowers the seizure threshold
[15,31]. Accordingly, selective blockade [8,9], or gene dele-
tion [9] of caspase-1, the enzyme which cleaves pro-IL-1β
producing the mature and biologically active form of IL-1β,
reduces seizures significantly. IL-1β could also affect
neuronal excitability at different levels [32? 34]. Both hy-
perexcitability and excitotoxicity are required and need to
be sufficient for the contributory effect of IL-1β to the
generation of SRS. Moreover, specific cytokines, includingIL-1β, have been shown to contribute to neuronal death
[35], perhaps in part via enhanced excitability [5]. Con-
versely, SE, in the absence of pre-existing or concomitant
systemic or CNS inflammation, induce proinflammatory
reactions in the brain (that is sterile inflammation), which
in turn contribute to seizure recurrence and severity [36].
Therefore, inflammation is both a cause and a conse-
quence of SE. Experimental studies show that once SE de-
velop, it can contribute to perpetuate inflammation in the
brain, thus activating a vicious cycle that in turn fosters
aberrant hyperexcitability (Figure 5). Thus, a prolonged
condition of ongoing seizures with SE can be generated.
Our study was to examine for first time whether the
NLRP3 inflammasome is a potential mechanism in neu-
roinflammation of SE rats. We compared expression of
proinflammatory cytokine IL-1β, NLRP3 and caspase-1
in hippocampus from SE rats model evoked by amygdala
stimulation to matched sham samples. The present study
detected up-regulated IL-1β, NLRP3 and caspase-1 levels
within SE samples than controls. All protein levels reach
a maximum at 12 hours following SE. Meanwhile, the
cellular localization of NLRP3 on microglia in SE rat
brain was demonstrated by double immunofluorescence
Figure 5 A schematic linking the nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3
(NLRP3) inflammasome activation to status epilepticus (SE) pathogenesis. Activation of the NLRP3 inflammasome typically requires a
bimodal signaling pathway. A Toll-like receptor (TLR)-dependent priming step activates the NF-κB-dependent transcription of NLRP3 and the
pro-forms of the proinflammatory cytokines (which are IL-1β and IL-18). NLRP3-activating stimulation agents provide a second signal in the form
of K+ efflux, cytosolic release of mitochondria-derived factors such as reactive oxygen species (ROS), cardiolipin, and oxidized mitochondrial DNA
(mtDNA). Note that acidic extracellular pH represents a novel stimulation agent for triggering NLRP3 inflammasome activation. Oligomerization
of NLRP3 is followed by recruitment of the adaptor molecule apoptosis-associated speck-like protein containing a caspase recruitment domain
(ASC) and the pro-form of caspase-1, leading to the activation (cleavage) of caspase-1. Activated caspase-1 in turn catalyzes the cleavage of IL-1β
and IL-18. This event may lead to changes in brain parenchyma such as leakage of the blood-brain barrier (BBB), neuronal hyperexcitability and
excitotoxicity as well as neuronal damage which contribute to lowering the threshold for seizure induction and thus to trigger epileptogenesis.
Activation of innate immune mechanisms during epileptogenesis can recruit inflammatory cells from the periphery which perpetuate
inflammation, thus activating a vicious cycle that in turn fosters aberrant hyperexcitability. The onset of SE can in turn further promote
inflammation via the production of proinflammatory cytokines.
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pression by implanting mini-osmotic pumps for direct
infusion of siRNA to investigate its role on neuroinflam-
mation in the SE rat model. In our study, we found that
this approach effectively down-regulated the levels of
NLRP3 mRNA and protein in SE rat brain. Meanwhile,
compared to non-siRNA-treated SE rat, the treatment
with control siRNA did not alter NLRP3 mRNA and pro-
tein levels, thus excluding an effect of pump-mediatedinfusion on NLRP3 expression levels. For the first time,
we revealed that NLRP3 siRNA treatment could signifi-
cantly reduce proinflammatory cytokine levels and the
active caspase-1 expression levels. Meanwhile, NLRP3 in-
hibition could also suppress SRS, and attenuate hippo-
campal neuronal loss.
As we know, caspase-1 is a critical pathway by which
NLRP3 inflammasomes contribute to the downstream ef-
fects. Hence, we also knocked down brain caspase-1 by this
Meng et al. Journal of Neuroinflammation 2014, 11:212 Page 11 of 12
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rats. Consistent biochemical and behavioral results were
found between caspase-1 siRNA- and NLRP3 siRNA-
treated SE rats, further supporting that NLRP3 exerts the
effects of neuroinflammation in rats following SE.
We have determined that the NLRP3 inflammasome
contributes to the SE-induced inflammatory response;
however, the molecular basis of NLRP3 inflammasome
activation in SE-induced brain injury has not been estab-
lished. Evidence shows that assembly of the NLRP3
inflammasome depends on the activation of NLRP3. This
process relies on exposure to whole pathogens, as well as
a number of structurally diverse pathogen or danger-
associated molecular patterns (PAMPs or DAMPs, re-
spectively) and environmental irritants. It should be noted
that, the high concentrations of extracellular ATP and K+
ions, and the generation of ROS are the most important
factors for activating NLRP3 [37]. In fact, all of the factors
above can be involved after SE. Additionally, it should be
noted that IL-1β may trigger the classical cascade of
events which includes the activation of the NF-κB-
dependent pathways, thus resulting in the transcription
of genes that may contribute to the acquired molecular
changes (for example, modifications in ion channels) as-
sociated with the epileptogenic process [38]. Interest-
ingly, NLRP3, an important component of the NLRP3
inflammasome complex, is activated by IKKβ/NF-κB
[12]. The activation of the NLRP3 inflammasome, results
in the secretion of bioactive IL-1β, and subsequently trig-
gers the activation of NF-κB which in turn promotes the
secretion of bioactive IL-1β [39]. Local acidosis has been
demonstrated at inflammatory sites. Recent data suggest
that acidosis is a regulator of inflammatory pathways
[16,40]. The study by Edye et al. [40] suggested that acid-
osis promotes alternative DAMP-induced processing of
IL-1β independent of caspase-1, and this result seemed to
be inconsistent with the findings by Rajam?ki and col-
leagues [16], as they found that acidic extracellular pH
triggers NLRP3 inflammasome activation and IL-1 secre-
tion in human macrophages (Figure 5).Conclusions
Our study firstly demonstrates that the expression of
the NLRP3 inflammasome was up-regulated in the SE
rat. The increase in NLRP3 levels can activate caspase-
1 signaling that is responsible for neuroinflammation,
neuronal loss and epileptogenesis (Figure 5). Using the
pump-mediated in vivo infusion of nonviral siRNA to
knock down NLRP3 and caspase-1 in the brain of SE
rats, our study further indicated that inhibition of
the NLRP3 inflammasome may play a neuroprotective
role against SE-related neuroinflammation and neur-
onal damage.Additional files
Additional file 1: Figure S1. Scheme of the experimental design and
the main experimental protocol. The rats were randomly divided into five
groups: sham group, SE group, control siRNA + SE group, NLRP3 siRNA +
SE group, and caspase-1 siRNA + SE group. siRNA, small interfering RNA;
SE, status epilepticus; TUNEL assay, terminal deoxynucleotidyl transferase-
mediated dUTP end-labeling assay; Elisa, enzyme-linked immunosorbent
assay; qRT-PCR, quantitative real-time PCR.
Additional file 2: Figure S2. Small interfering RNA (siRNA) targeting
NLRP3 or caspase-1 effectively downregulated NLRP3 or caspase-1 in
status epilepticus (SE) rat. (A) Messenger RNA levels of NLRP3 in brain of
SE rats after 6-week infusion of artificial cerebrospinal fluid (aCSF), control
siRNA or NLRP3 siRNA. (B) Protein levels of NLRP3 in brain of SE rats after
6-week infusion of artificial cerebrospinal fluid (aCSF), control siRNA, or
NLRP3 siRNA. (C) Messenger RNA levels of caspase-1 in brain of SE rats
after 6-week infusion of aCSF, control siRNA, or caspase-1 siRNA. (D)
Protein levels of caspase-1 in brain of SE rats after 6-week infusion of
aCSF, control siRNA or caspase-1 siRNA. Data are expressed as a fold
change relative to sham group. Columns represent mean ? standard
deviation. n = 6 rats per group. *P < 0.05 versus control siRNA treatment.
(E) Protein levels of NLRP3 in brain of sham rats after 6-week infusion of
control siRNA, or aCSF. (F) Protein levels of caspase-1 in brain of sham rats
after 6-week infusion of control siRNA oraCSF. Data are expressed as a
fold change relative to sham group. Columns represent mean ? standard
deviation. n = 6 rats per group. NS: not significant versus sham rats.
Additional file 3: Table S1. Pump-mediated infusion of small
interfering RNA (siRNA) prior to status epilepticus (SE) induction has no
potential effects directly on the development and severity of
spontaneous recurrent seizures (SRS).
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